EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade

Yuchen Zhang, Chen Yang, Yanchao Xu, Xiang Jiang, Jiajun Shi, Binghua Li, Decai Yu

Biomolecules and Biomedicine · 2024

DOI: 10.17305/bb.2024.11069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Yuchen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing D…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Programmed Cell Death 1 Receptor, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors produce durable antitumor effects in various cancers, but not all patients respond. High tumor mutational burden (TMB) is a known predictor of clinical benefit. In this study, we focused on the MHC-I-dependent neoantigen presentation pathway to enhance predictive capabilities beyond TMB. Using pan-cancer immunogenomic analyses of somatic mutation data from The Cancer Genome Atlas (TCGA) and The International Cancer Genome Consortium (ICGC), we analyzed 33 cancer types. Objective response rates (ORRs) to PD-1/PD-L1 inhibitors were evaluated in relation to immune characteristics, including TMB, neoantigen load, MHC-I gene expression, and CD8+ T cell fraction. Spearman’s rank correlation was used to assess these relationships. TMB showed the strongest correlation with ORR (r = 0.783, P = 2.17 × 10⁻⁵). However, integrating TMB, HLA-A expression, and CD8+ T cell fraction significantly improved predictive accuracy (r = 0.865, P = 1.80 × 10⁻⁶). Validation in external cohorts confirmed these findings, revealing notable differences in MHC-I pathway activity between responders and non-responders to immunotherapy. Our results demonstrate that the MHC-I antigen presentation pathway is strongly associated with response to PD-1/PD-L1 inhibitors. Importantly, combining antigen expression, processing, presentation, and recognition features provides superior predictive power compared to TMB alone. This integrated approach could improve treatment outcome predictions and advance personalized immunotherapy strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenProgrammed Cell Death 1 ReceptorNeoplasmsImmune Checkpoint InhibitorsAntigen PresentationAntigens, NeoplasmHistocompatibility Antigens Class IHumansCD8-Positive T-LymphocytesMutationImmunotherapy

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsCD274 protein, humanAntigens, NeoplasmHistocompatibility Antigens Class IPDCD1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medi…

Zitieren

APA

Zhang, Y., Yang, C., Xu, Y., Jiang, X., Shi, J., Li, B., & Yu, D. (2024). The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.11069

Vancouver

Zhang Y, Yang C, Xu Y, Jiang X, Shi J, Li B, et al. The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.11069

BibTeX
@article{Zhang2024,
  author = {Zhang, Yuchen and Yang, Chen and Xu, Yanchao and Jiang, Xiang and Shi, Jiajun and Li, Binghua and Yu, Decai},
  title = {The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade},
  journal = {Biomolecules and Biomedicine},
  year = {2024},
  doi = {10.17305/bb.2024.11069}
}
Kostenlos starten →